T2 Biosystems Q2 Revenues Up, But Impacted by Recent Test Cartridge Shipment Hold | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market on Monday a 75 percent jump in second quarter revenues, which were buoyed by increased research revenues but negatively impacted by a previously announced hold on shipments of its sepsis test cartridges.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.